Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

Breast cancer research : BCR | 2011

Infiltration of breast tumors by tumor-infiltrating lymphocytes (TIL) has been associated with sensitivity to anthracycline-based chemotherapy. However, it is unclear whether this is true within the estrogen receptor-alpha (ER)-negative subset of breast tumors that frequently manifest high TIL levels.

Pubmed ID: 22151962 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Canadian Institutes of Health Research, Canada
    Id: MOP-64349
  • Agency: Canadian Institutes of Health Research, Canada
    Id: PRG80155

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Manitoba Breast Tumor Bank (tool)

RRID:SCR_008723

A collection of tissue and related clinical data for breast cancer. The Bank stores three types of information on each case within a secure location in CancerCare Manitoba. This information relates to the tissue, clinical, and follow-up information. Tissue information includes the composition of the tissue, the size and type of tumor. Clinical information includes the patient age, clinical symptoms and the results of clinical tests such as x-rays. Follow-up information includes the type of treatment after surgery and the response to this treatment. The Bank provides an important resource both for breast cancer research at the University of Manitoba and for researchers across Canada and internationally. Researchers are charged to cover the costs of storage and release but no tissue or information is sold. The Bank has supported over 50 research studies on breast cancer across North America and Europe. Information is never released from the Bank with any label that might allow it to be traced to an individual. Information is only released as part of a set of anonymized cases, where each case is labeled by an anonymous tumor bank number and consists of a section of tissue with related information. Researchers can apply to study these cases only through a review process and if they obtain approval for their research project from an institutional ethics review board. If approved, researchers are provided with tissue sections and the related clinical information from a set of typically 100 or more ����??cases����??. These cases are carefully selected from the computer database on the basis of selection criteria such as size and type of tumor that are relevant to the research question under study. During the assessment of each breast biopsy specimen small tissue samples are taken by Pathologists to process and examine under a microscope and these samples are then stored as a ����??clinical archive����??. After all diagnosis has been completed the Bank organizes these tissues and related clinical data into ����??cases����?? for both future research and future clinical purposes and stores these ����??cases����?? in CancerCare Manitoba. All cases are distinguished by a Tumor Bank number but are anonymous due to the absence of any tag that might allow it to be traced to an individual patient.

View all literature mentions

EORTC (tool)

RRID:SCR_004070

An independent pan-European clinical research organization to improve the standards of cancer care through the multidisciplinary multinational efforts of basic scientists and clinicians. The efforts include the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. They also contribute to the development of new drugs and other approaches in partnership with the pharmaceutical industry which is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. The EORTC Network comprises over 300 hospitals and cancer centers in over 30 countries which include some 2,500 collaborators from all disciplines involved in cancer treatment and research. The EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Intergroup collaboration is also promoted to face current challenges of clinical trials aiming at targeted therapies in order to recruit a large number of patients within a reasonable period of time.

View all literature mentions

Cluster (tool)

RRID:SCR_013505

Software R package. Methods for Cluster analysis. Performs variety of types of cluster analysis and other types of processing on large microarray datasets.

View all literature mentions